Literature DB >> 19015148

Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.

Hiromi Ishihama1, Masayuki Chida, Osamu Araki, Yoko Karube, Norio Seki, Motohiko Tamura, Hideo Umezu, Koichi Honma, Nobuhide Masawa, Shinichiro Miyoshi.   

Abstract

BACKGROUND: A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas.
METHODS: We investigated the 5-FU-related gene expression levels of thymidylate synthase (TS), DPD, thymidine phosphorylase (TP) and orotate phosphoribosyl transferase (OPRT) in resected tumor specimens from 51 patients with adenocarcinomas and 47 with squamous cell carcinomas using quantitative reverse transcription-PCR, and compared those levels between the two histological types.
RESULTS: The relative gene expression values of TS, TP and OPRT were significantly lower in adenocarcinomas compared with squamous cell carcinomas, 1.60 +/- 0.86 versus 4.33 +/- 3.40 (P < 0.001), 0.84 +/- 0.52 versus 2.27 +/- 1.16 (P = 0.006) and 9.59 +/- 6.30 versus 16.94 +/- 12.04 (P < 0.001), respectively. The relative gene expression value of DPD was significantly greater in adenocarcinomas than those in squamous cell carcinomas, 2.33 +/- 1.22 versus 1.50 +/- 1.20 (P = 0.01). Lower expressions of TS and TP were observed more in adenocarcinomas (89.8%) than in squamous cell carcinomas (48.9%) (P < 0.001).
CONCLUSION: These data may explain that post-operative adjuvant chemotherapy with UFT was associated with improved survival in stage I patients with adenocarcinoma, but less with squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015148     DOI: 10.1093/jjco/hyn121

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  10 in total

1.  Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma.

Authors:  Kyoichi Kaira; Yasuhisa Ohde; Kazuo Nakagawa; Takehiro Okumura; Haruyasu Murakami; Toshiaki Takahashi; Haruhiko Kondo; Takashi Nakajima; Masahiro Endo; Nobuyuki Yamamoto
Journal:  Med Oncol       Date:  2011-09-24       Impact factor: 3.064

2.  Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.

Authors:  Naoya Himuro; Yumiko Niiya; Takao Minakata; Yutaka Oshima; Daisuke Kataoka; Shigeru Yamamoto; Takashi Suzuki; Mitsutaka Kadokura
Journal:  Mol Clin Oncol       Date:  2018-09-25

3.  Identification of thymidylate synthase as a potential therapeutic target for lung cancer.

Authors:  K Takezawa; I Okamoto; S Tsukioka; J Uchida; M Kiniwa; M Fukuoka; K Nakagawa
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

Review 4.  Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC.

Authors:  Ali A Bukhari; Ranjit K Goudar
Journal:  Lung Cancer Int       Date:  2013-12-25

5.  Tumor-related gene expression levels in pulmonary pleomorphic carcinoma.

Authors:  Takeshi Oyaizu; Yuji Matsumura; Satoru Kobayashi; Tetsu Sado; Hiromi Ishihama; Masayuki Chida
Journal:  J Cardiothorac Surg       Date:  2015-06-03       Impact factor: 1.637

6.  Tumor-related gene expression levels in thymic carcinoma and Type B3 thymoma.

Authors:  Yoko Karube; Satoru Kobayashi; Sumiko Maeda; Tetsu Sado; Hiromi Ishihama; Masayuki Chida
Journal:  J Cardiothorac Surg       Date:  2016-05-26       Impact factor: 1.637

7.  Expression of thymidylate synthase predicts clinical outcomes of S-1-based chemotherapy in squamous cell lung cancer.

Authors:  Yuichiro Honma; Shinsaku Togo; Kazue Shimizu; Miniwan Tulafu; Takuo Hayashi; Toshimasa Uekusa; Shigeru Tominaga; Kenji Kido; Yuichi Fujimoto; Yukiko Nanba; Kazuya Takamochi; Shiaki Oh; Kenji Suzuki; Kazuhisa Takahashi
Journal:  Oncol Lett       Date:  2017-07-19       Impact factor: 2.967

8.  The impact of pharmacokinetic gene profiles across human cancers.

Authors:  Michael T Zimmermann; Terry M Therneau; Jean-Pierre A Kocher
Journal:  BMC Cancer       Date:  2018-05-21       Impact factor: 4.430

9.  Expression of thymidylate synthase and orotate phosphoribosyltransferase in thymic carcinoma.

Authors:  Keisuke Yokota; Hidefumi Sasaki; Katsuhiro Okuda; Masayuki Shitara; Yu Hikosaka; Satoru Moriyama; Motoki Yano; Yoshitaka Fujii
Journal:  Exp Ther Med       Date:  2012-07-19       Impact factor: 2.447

10.  Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review.

Authors:  Hong Tang; Hongyan Wang; Shaoyan Xi; Chunyu He; Yuxi Chang; Qiming Wang; Yufeng Wu
Journal:  Onco Targets Ther       Date:  2018-05-07       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.